Effects of troglitazone and pioglitazone on cytokine-mediated endothelial cell proliferation in vitro

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 6, 1998, Pages 909-913

  Gralinski, Michael R ^a,b   Rowse, Paul E ^a   Breider, Michael A ^a  

^a PFIZER INC   (United States)

^b Product Safety Assessment   (United States)

Author keywords

Endothelium; Mouse; Restenosis; Thiazolidinediones

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; PIOGLITAZONE; TROGLITAZONE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; DIABETES MELLITUS; DRUG EFFECT; ENDOTHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ANIMALS; CELL DIVISION; CHROMANS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HYPOGLYCEMIC AGENTS; INSULIN; MICE; MICE, INBRED BALB C; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031750208     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199806000-00015     Document Type: Article

References (23)

1. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988;37:1549-58.
2. Hofmann C, Lorenz K, Colca JR. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 1991;129:1915-25.
3. Tominaga M, Igarashi M, Daimon M, et al. Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J 1993;40:343-9.
4. Kuehnle HF. New therapeutic agents for the treatment of NIDDM. Exp Clin Endocrinol Diabetes 1996;104:93-101.
5. Kuzuya T, Iwamoto Y, Kosaka K, et al. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1991;11: 147-53.
6. Shimabukuro M, Higa S, Shinzato T, Nagamine F, Komiya I, Takasu N. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 1996;45:1168-73.
7. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-905.
8. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993;265:R726-32.
9. Schweigerer L. Fibroblast growth factor and angiogenesis. Z Kardiol 1989;78(suppl 6):12-5.
10. Sato Y, Shimada T, Takaki R. Autocrinological role of basic fibroblast growth factor on tube formation of vascular endothelial cells in vitro. Biochem Biophys Res Commun 1991;180: 1098-102.
11. Villaschi S, Nicosia RF. Angiogenic role of endogenous basic fibroblast growth factor released by rat aorta after injury. Am J Pathol 1993;143:181-90.
12. Chen HH, Chien CH, Liu HM. Correlation between angiogenesis and basic fibroblast growth factor expression in experimental brain infarct. Stroke 1994;25:1651-7.
13. Nissen NN, Polverini PJ, Gamelli RL, DiPietro LA. Basic fibroblast growth factor mediates angiogenic activity in early surgical wounds. Surgery 1996;119:457-65.
14. Twentyman PR, Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987;56:279-85.
15. van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MM. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 1994;174:311-20.
16. Peuler JD, Phare SM, Iannucci AR, Hodorek MJ. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens 1996;9:188-92.
17. Morikang E, Benson SC, Kurtz TW, Pershadsingh HA. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 1997;10:440-6.
18. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996;19:151-6.
19. Iwamoto Y, Kuzuya T, Matsuda A, et al. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 1991;14:1083-6.
20. el Kebbi IM, Roser S, Pollet RJ. Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 1994;43:953-8.
21. Stout RW. Insulin as a mitogenic factor. role in the pathogenesis of cardiovascular disease. Am J Med 1991;90:62S-5S.
22. Weinstein R, Wenc K. Growth factor responses of human arterial endothelial cells in vitro. In Vitro Cell Dev Biol 1986;22:549-56.
23. Rak R, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiosenesis. Cancer Metastasis Rev 1995;14:263-77.